Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.
Fibrotic processes are the root cause behind a variety of hard-to-treat diseases, and are key to the scientific approach used by Agomab Therapeutics NV, a Belgian biotech which aims...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.
While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
